Navigation Links
Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
Date:6/13/2013

MADRID, June 13, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) today announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study of baricitinib in patients with active rheumatoid arthritis (RA). Baricitinib, formerly LY3009104 (INCB28050), is an orally available Janus kinase (JAK) inhibitor being studied for use in the treatment of certain autoimmune conditions, including RA. Among patients completing the open-label extension, clinical improvements observed at week 24 were sustained at the end of 52 weeks. The results were presented at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Madrid, Spain [EULAR abstract OP0047: Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Study].

The long-term extension of the JADA study evaluated the efficacy and safety of baricitinib in 201 patients taking either 4 mg (n=108) or 8 mg (n=93) once daily for up to 52 weeks. Doses could be escalated to 8 mg once daily at 28 or 32 weeks at the investigator's discretion when the patient presented more than six tender and swollen joints.

As previously reported, in the initial 12-week portion of this study, baricitinib was associated with statistically significant improvements in the signs and symptoms of RA disease versus placebo[1] and these responses were maintained or improved during an additional 12 weeks of blinded treatment.[2]

In the long-term extension, the clinical improvements observed at week 24 were sustained through 52 weeks in RA patients. The following chart summarizes selected efficacy results:

<
'/>"/>
SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lilly to Present at Goldman Sachs Global Healthcare Conference
2. Lilly Acquires Novel Tau Tangle Diagnostic Program to Bolster Alzheimers Disease Research and Development
3. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
4. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
5. Todays Research on Incyte and Arena Pharma: Biotech Stocks Up on Drug Approvals
6. Steep Hill Laboratories and Halent Scientific Proudly Announce Historic Merger
7. Andain Inc. Announces 2,000 Units Initial Production of the Breakthrough Miniature Disposable Insulin Pump for Use in Clinical Trials for Type-I and Type-II Diabetes
8. Verenium Announces Appointment Of Brian Carter As Vice President Of Grain Processing
9. Neogen announces Bohannon retirement, successor named
10. BioDelivery Sciences Announces NDA Submission for BUNAVAIL on Track Following Positive Pre-NDA Meeting with FDA
11. Hemostemix Announces Formation of Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Genedata, a leading provider ... and related life science research, today announced ... Selector as its host-pathogen data analysis platform ... a European consortium dedicated to improving the ... anti-fungal drug therapies. Genedata Selector supports this ...
(Date:9/30/2014)... , Sept. 30, 2014 FemCap Inc., ... health announces its receipt of a patent No: US, ... cup has also received FDA clearance in the U.S., ... the CE in Europe. This patent is related to its ... this issuance, the company is releasing FemmyCycle Teen, a ...
(Date:9/30/2014)... 2014 Lyme Research Alliance ... disease research at universities, today announced the awarding of ... identification, treatment and cure for Lyme and other tick-borne ... most applications in its history—over 20 grant proposals—a 100 ... were pleased to receive so many solid applications from ...
(Date:9/30/2014)... Georgetown, Mass. (PRWEB) September 30, 2014 ... components, products, and specialty packaging has recently introduced ... BioShell® Suspension Pack . The new insulated ... the cold chain distribution process. UFP Technologies’ BioShell ... use biopharmaceutical bags during storage, handling and shipping. ...
Breaking Biology Technology:FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3The FemmyCycle 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3
... to add new apoA1 measurement and apoB:apoA1 ratio to its, ... ... heart disease, BIRMINGHAM, Ala., Nov. 6 ... its VAP(R),Cholesterol Test in booth No. 2918 at the American Heart ...
... Inc. (Pink,Sheets: SNDY) is pleased to announce that the ... from the St. Mary,s,Hospital in Waterbury, CT. St. Mary,s ... yrs and it has chosen to continue using the,Company,s ... vital role in the history of Greater,Waterbury, providing nearly ...
... Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) announced today that it ... Global Investment Conference to be held,November 10-12, 2008 at ... of,Access is scheduled to speak on Tuesday, November 11, ... corporate overview and discuss the Company,s,product opportunities., The ...
Cached Biology Technology:Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008 2Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital 2Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference 2
(Date:9/29/2014)... at Washington State University have concluded that nondigestible ... may help prevent disorders associated with obesity. ... assess these compounds in apple cultivars grown in ... of the journal Food Chemistry ., "We ... source of these nondigestible compounds but there are ...
(Date:9/29/2014)... Behavioral Brain Research provides novel insight into ... of chronic alcohol exposure that can lead to disruptions ... research indicate that individuals with alcohol use disorders frequently ... people are actively drinking, when they are going through ... disturbances can last for months, or even years, after ...
(Date:9/29/2014)... Pangea was starting to break up and dog-sized dinosaurs were ... phytosaurs and rauisuchids were at the top of the food ... didn,t interact much as the former was king of the ... are changing, thanks largely to the contents of a single ... the German journal Naturwissenschaften , Stephanie Drumheller ...
Breaking Biology News(10 mins):An apple a day could keep obesity away 2Tooth buried in bone shows prehistoric predators tangled across land, sea 2
... of Oceanography at UC San Diego have developed a ... algae. As reported in this week,s online edition ... Sciences , Scripps graduate student Emily Trentacoste led the ... growth component in biofuel production. In the quest ...
... In what is anticipated to be a major step ... Cell Foundation (NYSCF) Research Institute is partnering with the ... NYSCF scientists will generate stem cell lines from ... researchers to better understand and potentially treat select rare ...
... Smaller bowl sizes may be the next weapon in the battle ... in the Journal of Pediatrics which found children not ... also eat 52 percent more. , "The quickest way parents ... smaller bowl," comments Brian Wansink, professor of behavioral economics and the ...
Cached Biology News:Scripps oceanography researchers engineer breakthrough for biofuel production 2NYSCF and NIH create cell models of rare and undiagnosed diseases 2NYSCF and NIH create cell models of rare and undiagnosed diseases 3
... designed to stabilize the biomolecules during ... There are neither animal proteins ... a convenient 10 times solution in ... to other traditional lyophilizing additives such ...
... benchtop incubator-shaker, has the smallest footprint of all ... 540 x 680 mm (W x D) does ... 505 x 510mm). Available in 25 mm or ... for shaking applications requiring controlled speed and temperature ...
... the smallest thermal cyclers on the market, which ... 0.5ml (20 samples) or 0.2ml microtube (25 samples) ... and cooling rate of 3.6C/sec and 2.0C/sec respectively ... Fast track programming with new quick dial facility ...
... StabilZyme HRP Conjugate Stabilizer is an ... protein and other non-toxic stabilizing chemicals in ... 6.2 6.7. This product contains ... and 20 ppm Proclin 300 (Rohm and ...
Biology Products: